Overview

EXTEND (International): Extending the Time for Thrombolysis in Emergency Neurological Deficits (International)

Status:
Completed
Trial end date:
2018-08-22
Target enrollment:
Participant gender:
Summary
The primary hypothesis being tested in this trial is that ischaemic stroke patients selected with significant penumbral mismatch (according to imaging criteria) at 4.5 (or 3 hours depending on local guidelines) - 9 hours post onset of stroke or after 'wake up stroke' (WUS) will have improved clinical outcomes when given intravenous tissue plasminogen activator (tPA) compared to placebo.
Phase:
Phase 3
Details
Lead Sponsor:
Neuroscience Trials Australia
Collaborator:
China Medical University Hospital
Treatments:
Plasminogen
Tissue Plasminogen Activator